Overview

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

Status:
RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, multicenter phase 3 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.
Phase:
PHASE3
Details
Lead Sponsor:
Ausper Biopharma Co., Ltd.